Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children

Pediatric Hematology and Oncology

Volumn 21, Issue 2, 2004, Pages 115-123

  Aksoylar, Serap ^a,b   Çetingül, Nazan ^a   Kantar, Mehmet ^a   Karapinar, Deniz ^a   Kavakli, Kaan ^a   Kansoy, Savaş ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Aminoglycoside; Cancer; Children; Febrile neutropenia; High risk; Meropenem; Piperacillin tazobactam

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIINFECTIVE AGENT; CILASTATIN PLUS IMIPENEM; FLUCONAZOLE; GROWTH FACTOR; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ADVANCED CANCER; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; CANCER STAGING; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENDER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HUMAN; LEUKEMIA; MALE; MICROBIOLOGICAL EXAMINATION; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; SIDE EFFECT;

AMIKACIN; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEVER; FUNGI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEMATOLOGIC NEOPLASMS; INFECTION; NEOPLASMS; NETILMICIN; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; THIENAMYCINS;

EID: 12144287504     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010490277321     Document Type: Article

References (23)

1. Alexander SW, Walsh TJ, Freifeld AG, Pizzo PA. Infectious complications in the paediatric cancer patients. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Paediatric Oncology, ed 4. Philadelphia: Lippincott Williams & Wilkins; 2002;1239-1283.
2. Petrilli AS, Melaragno R, Barros KVT, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J. 1993;12:916-921.
3. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77:791-798.
4. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38-42.
5. Klaassen RJ, Goodman R, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients. J Clin Oncol. 2000;18:1012-1019.
6. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
7. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin of meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001 Jun;13:281-287.
8. Duzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr. 2001;43:105-109.
9. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841-853.
10. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenia patients: a prospective randomized pilot study. Eur J Med Res. 1998;3:324-330.
11. Del Favero A, Menichetti F, Martino P, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295-1301.
12. Hess U, Bohme C, Rev K, Senn HJ. Monotherapy with piperacillin-tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer. 1998;6:402-409.
13. Sanz MA, Lopez J, Lahuerta JJ, et al. Spanish PETHEMA Group. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother. 2002;50:79-88.
14. Bauduer F, Cousin T, Boulat O, et al. BGMT Collaborative Group. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma. 2001;42:379-386.
15. Marie JP, Marjanovic Z, Vekhoff A, et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Support Care Cancer. 1999;7:89-94.
16. Jorgensen JH, Ferraro MJ, Craig WA, et al. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Tests, ed 6. Approved Standard. M2-A6, 17:1, NCCLS, Pennsylvania, 1997.
17. Kebudi R, Gorgun O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001;36:434-441.
18. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two cancer validation of a prediction rule. J Clin Oncol. 1992;10:316-322.
19. Feld R, DePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized double-blind trial. J Clin Oncol. 2000;18:3690-3698.
20. Vandercam B, Gerain J, Hunblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol. 2000;79:152-157.
21. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother. 1996;8:375-381.
22. Figuera A, Rivero N, Pajuelo F, et al. Comparative study of piperacillin/tazobactam versus imipenem/ cilastatin in febrile neutropenia (1994-1996). Med Clin (Barc). 2001;116:610-611.
23. Kern WV, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med. 1999;341:312-318.